Quick Answer
MADRIGAL PHARMACEUTICALS, INC. reported Earnings Per Share Diluted of $12.85 (loss) per share for the year ending 2025.
- MADRIGAL PHARMACEUTICALS, INC. showed an increase of +41.3% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from MADRIGAL PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
- XBRL data for this metric is available from 2009 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $3.32 (loss) per share | Q2 2021: $3.72 (loss) per share | Q3 2021: $3.79 (loss) per share | Q4 2021: $3.78 (loss) per share | Q1 2022: $3.36 (loss) per share | Q2 2022: $4.14 (loss) per share | Q3 2022: $4.75 (loss) per share | Q4 2022: $4.98 (loss) per share | Q1 2023: $4.23 (loss) per share | Q2 2023: $4.69 (loss) per share | Q3 2023: $5.34 (loss) per share | Q4 2023: $5.68 (loss) per share | Q1 2024: $7.38 (loss) per share | Q2 2024: $7.10 (loss) per share | Q3 2024: $4.92 (loss) per share | Q1 2025: $3.32 (loss) per share | Q2 2025: $1.90 (loss) per share | Q3 2025: $5.08 (loss) per share.
- Over the full 9 years of available data (2009 to 2025), MADRIGAL PHARMACEUTICALS, INC.'s Earnings Per Share Diluted has declined by 653.9%.
- Historical annual values: Fiscal year 2025: $12.85 (loss) per share | Fiscal year 2024: $21.90 (loss) per share | Fiscal year 2023: $19.99 (loss) per share | Fiscal year 2022: $17.23 (loss) per share | Fiscal year 2021: $14.63 (loss) per share | Fiscal year 2020: $13.09 (loss) per share | Fiscal year 2011: $1.00 (loss) per share | Fiscal year 2010: $0.93 (loss) per share | Fiscal year 2009: $2.32 per share.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: